Results 1 to 10 of about 33,513 (195)

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

International Journal of Nephrology and Renovascular Disease, 2010
Elizabeth Ripley, Ari HirschDivision of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USAAbstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago.During those years, researchers and clinicians have ...
Elizabeth Ripley
exaly   +3 more sources

Oral losartan yields subtherapeutic airway exposure compared to nebulized delivery and fails to improve mucociliary clearance in cystic fibrosis [PDF]

Frontiers in Pharmacology
BackgroundTransforming growth factor-β1 (TGF-β1) contributes to more severe pulmonary disease in people with cystic fibrosis (pwCF). Our preclinical in vitro and in vivo studies demonstrated that losartan could reverse TGF-β1-mediated mucociliary ...
Charles D. Bengtson, Andreas Schmid, Michael D. Kim, John S. Dennis, J. Steven Leeder, Kirby L. Zeman, William D. Bennett, Juan Sabater, Nathalie Baumlin, Matthias Salathe   +9 more
doaj   +2 more sources

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer [PDF]

BioImpacts, 2023
Introduction: Immune checkpoint inhibitors (ICIs) have provided noteworthy benefits in multiple cancer patients. However, the efficacy of monotherapy of ICIs was very limited.
Xiuying Li, Xianqin Luo, Shunqin Hu
doaj   +1 more source

Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: A propensity score-matched analysis

Frontiers in Oncology, 2022
BackgroundCholangiocarcinoma (CCA) is a malignant tumor originating from bile duct epithelial cells that no obvious clinical symptoms and specific clinical manifestations are shown in the early stage of CCA.MethodsPropensity score matching (PSM) is a ...
Qing Li, Zhenyu Chang, Zhenyu Chang, Tianyi Wang, Bing Liu, Ximin Wang, Xin-Yu Ge, Tao Yang, Qu Liu, Qu Liu, Wei Wang   +10 more
doaj   +1 more source

Changes in Pharmacokinetics and Pharmacodynamics of Losartan in Experimental Diseased Rats Treated with Curcuma longa and Lepidium sativum

Pharmaceuticals, 2022
The current study investigated “pharmacodynamics and pharmacokinetics interactions” of losartan with Curcuma longa (CUR) and Lepidium sativum (LS) in hypertensive rats.
Abdul Ahad, Mohammad Raish, Ibrahim Abdelsalam Abdelrahman, Yousef A. Bin Jardan, Mohd Aftab Alam, Abdullah M. Al-Mohizea, Fahad I. Al-Jenoobi   +6 more
doaj   +1 more source

COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients

Contemporary Clinical Trials Communications, 2022
Objectives: To assess the efficacy and safety of losartan for COVID-19 patients. Methods: COVIDMED was a double-blinded, placebo-controlled platform RCT.
Daniel Freilich, Jennifer Victory, Paul Jenkins, Anne Gadomski   +3 more
doaj   +1 more source

Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model

Radiation Oncology, 2021
Background Patients with metastatic HER2/neu-positive (HER2/neu +) breast cancer (BC) often experience treatment resistance, disease recurrences and metastases.
Wende Li, Sen Li, Ivy X. Chen, Yujiao Liu, Rakesh R. Ramjiawan, Chi-Ho Leung, Leo E. Gerweck, Dai Fukumura, Jay S. Loeffler, Rakesh K. Jain, Dan G. Duda, Peigen Huang   +11 more
doaj   +1 more source

Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects

Фармакокинетика и Фармакодинамика, 2022
Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier to ...
A. L. Khokhlov, D. Yu. Grebenkin, E. K. Faeva, V. I. Kazey, A. A. Khokhlov, A. E. Miroshnikov, O. V. Lebedeva   +6 more
doaj   +1 more source

P50 The Administration of Losartan/Amlodipine in Fixed Combination Versus Losartan Improves the Hemodynamic and Arterial Stiffness Parameters in Patients with Systemic Hypertension Grade 1 and 2

Artery Research, 2020
Purpose/Background/Objectives: Hypertension (HAS) represents 9.4 million deaths from all the cases of cardiovascular disease worldwide [1]. The pulse wave velocity (PWV) and some hemodynamic parameters have been associated with this outcome [2,3 ...
Mayra Jimenez, Fernando Grover, Marycruz Barocio, Ernesto Cardona, Patricia Quezada, Jhonatan Trujillo, David Cardona, Carlos Ramos   +7 more
doaj   +1 more source

The beneficial effect of intra-articular injection of losartan on the microfracture mediated cartilage repair is dose dependent

Orthopaedic Journal of Sports Medicine, 2021
Objectives: 1. To determine the dosage and beneficial effects of intra-articular injection of losartan on microfracture-mediated cartilage repair and normal cartilage homeostasis.
Xueqin Gao, Hajime Utsunomiya, Alex Scibetta, Sudheer Ravuri, Joseph Ruzbarsky, Camille Talwar, Justin Arner, Walter Lowe, Marc Philippon MD, Johnny Huard, Catherine Logan MD, MSPT, MBA   +10 more
doaj   +1 more source